
    
      This is a single center, open-label, single oral dose study in healthy Japanese adult male
      participants. The study consists of 3 phases; a screening phase up to 27 days (Day -28 to Day
      -2), an in-patient phase from Day -1 to Day 3 (dosing day is Day 1), and a follow-up
      assessment phase from Day 4 to the last follow-up assessment scheduled on Day 15 or at the
      time of early withdrawal. All participants will receive a single oral dose of one Complera
      tablet on Day 1 within 5 minutes after completion of the standardized breakfast.
      Pharmacokinetics of RPV/TFV/FTC will be assessed as the primary objective of the study.
      Safety of each participant will be assessed throughout the study.
    
  